Third-quarter flash report came in
Analyst consensus available
Gynaecological product gets green light, milestone payment coming
Vrylar, jointly developed with US partner AbbVie, is the subject of the positive news
Some fear it could set back the development of treatments for rare diseases
The pharmaceutical manufacturer did not disappoint
EcoMin reveals who can be exempted and how
Márton Nagy says the pharmaceutical sector no longer makes extra profit
Analysts surveyed
Into a single giant company.
Higher TP with 'Overweight' recommendation
Richter will become 100% owner of the two companies for €112 million
Erik Bogsch replaced by E. Szilveszter Vizi
From Erste
Just to be clear about the impacts
In addition to the already existing special tax
With HUF 200 billion and more favourable interest rates
Management addresses Q3 earnings and more
Results largely exceed analyst expectations, though
Battle against endometriosis continues